FINAL DIAGNOSIS:

PART 1: BREAST, RIGHT, NEEDLE LOCALIZED SEGMENTAL MASTECTOMY -

INVASIVE DUCTAL CARCINOMA, 1.9 CM (GROSS), NOTTINGHAM GRADE 2 (COMBINED NOTTINGHAM SCORE 6/9: TUBULE FORMATION 3/3, NUCLEAR ATYPIA 2/3, MITOTIC ACTIVITY 1/3).

B. DUCTAL CARCINOMA IN SITU, EXTENSIVE, SOLID TYPE NUCLEAR GRADE 2, WITH LOBULAR CANCERIZATION AND FOCAL COMEDO TYPE NECROSIS, ASSOCIATED WITH INVASIVE TUMOR AND COMPRISES MORE THAN 25% OF TUMOR VOLUME.

C. LYMPHOVASCULAR INVASION IS IDENTIFIED.

D. MARGINS FREE, CLOSEST ANTERIOR WITHIN 0.4 CM, SECOND CLOSEST POSTERIOR WITHIN 0.5 CM.

E. SCLEROSING ADENOSIS.

F. FIBROADENOMATOID CHANGES.

G. BIOPSY SITE CHANGES.

H. PATHOLOGIC STAGE (see comment).

PART 2: SENTINEL LYMPH NODE NUMBER 1, BIOPSY -ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1).

PART 3: SENTINEL LYMPH NODE NUMBER 2, BIOPSY -ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1).

CASE SYNOPSIS:

SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST

LATERALITY: PROCEDURE:

Right

Segmental

LOCATION:

Not specified

SIZE OF TUMOR:

Maximum dimension invasive component: 1.9 cm

100-0-3

Carcinoma, infiltrating ductal, was \$500/3

Site: brust, NOS C50.9 3/13/11 he

MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI:

No

TUMOR TYPE (invasive component):

NOTTINGHAM SCORE:

Ductal adenocarcinoma, NOS

Nuclear grade: 2 Tubule formation: 3 Mitotic activity score: 1

Total Nottingham score: 6 Nottingham grade (1, 2, 3): 2

ANGIOLYMPHATIC INVASION:

Yes

DERMAL LYMPHATIC INVASION:

Not applicable

CALCIFICATION: TUMOR TYPE, IN SITU:

No Solid

Percent of tumor occupied by in situ component: 35 % SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT:

No

SURG MARGINS INVOLVED BY IN SITU COMPONENT:

LYMPH NODES POSITIVE:

No 0

LYMPH NODES EXAMINED:

METHOD(S) OF LYMPH NODE EXAMINATION:

T STAGE, PATHOLOGIC:

H/E stain pT1c

N STAGE, PATHOLOGIC:

pN0

M STAGE, PATHOLOGIC:

XMq

ESTROGEN RECEPTORS:

positive

PROGESTERONE RECEPTORS:

positive

HER2/NEU:

2+

1 to 1 m -		
UUID: C7476B2B-0040-4013	-8D30-06935E3F	B897
TCGA-BH-AØHB-Ø1	A-PR	Redacted
		1 888 18 1 81 1 1
		
3(1 38 0 9 9 1 1 1 1 1 1 1 1		

Criteria	Yes	NO.
	" l	
Diagnosis Discrepancy		
Primary Tumor Site Discrepancy		
HIPAA Discrepancy		
Prior Malignancy History		
Dual/Synchronous Primary Nated	ISDUALITIED	
Case is (circle):		
Reviewer Initials Date Reviewed:	7,12,1	·
	// -	
	113/H	1 1
	1	